These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27890426)

  • 1. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
    Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
    Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
    Evans JR; Zhao S; Daignault S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki J; Kaplan ID; Zietman AL; Hembroff L; Feng FY; Suy S; Skolarus TA; McLaughlin PW; Wei JT; Dunn RL; Finkelstein SE; Mantz CA; Collins SP; Hamstra DA;
    Radiother Oncol; 2015 Aug; 116(2):179-84. PubMed ID: 26276528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
    Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE
    Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
    Katz A; Ferrer M; Suárez JF;
    Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
    Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Tong M; Wu B; Lei S; Obayomi-Davies O; Chen LN; Suy S; Dritschilo A; Yorke E; Collins SP
    Acta Oncol; 2016; 55(1):52-8. PubMed ID: 25972264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
    Rucinska M; Kieszkowska-Grudny A; Nawrocki S
    Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
    Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):823-833. PubMed ID: 30458234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
    Quon HC; Ong A; Cheung P; Chu W; Chung HT; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
    Radiother Oncol; 2018 May; 127(2):206-212. PubMed ID: 29551231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
    Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
    Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proctitis following stereotactic body radiation therapy for prostate cancer.
    Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
    Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
    Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
    Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
    Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.
    Hoffman KE; Skinner H; Pugh TJ; Voong KR; Levy LB; Choi S; Frank SJ; Lee AK; Mahmood U; McGuire SE; Schlembach PJ; Du W; Johnson J; Kudchadker RJ; Kuban DA
    Am J Clin Oncol; 2018 Jun; 41(6):558-567. PubMed ID: 27635624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
    Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
    Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
    Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
    Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
    Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer.
    Tambas M; Agaoglu F; Iribas A; Guveli M; Dizdar Y; Okutan M; Sahin D; Tenekeci N; Darendeliler E
    Value Health Reg Issues; 2016 Sep; 10():91-99. PubMed ID: 27881285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.